Targeting the Ezrin Adaptor Protein Sensitizes Metastatic Breast Cancer Cells to Chemotherapy and Reduces Neoadjuvant Therapy-induced Metastasis.
Journal
Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
03
11
2021
revised:
05
05
2022
accepted:
20
05
2022
entrez:
16
3
2023
pubmed:
17
3
2023
medline:
17
3
2023
Statut:
epublish
Résumé
The main cause of cancer-associated deaths is the spread of cancer cells to distant organs. Despite its success in the primary tumor setting, modern chemotherapeutic strategies are rendered ineffective at treating metastatic disease, largely due to the development of resistance. The adaptor protein ezrin has been shown to promote cancer metastasis in multiple preclinical models and is associated with poor prognosis in several cancer types, including breast cancer. Ezrin promotes pro-survival signaling, particularly in disseminated cancer cells, to facilitate metastatic outgrowth. However, the role of ezrin in breast cancer chemoresistance is not fully known. In this study, we show that upregulating or downregulating ezrin expression modifies the sensitivity of breast cancer cells to doxorubicin and docetaxel treatment This work provides preclinical evidence for combining anti-ezrin treatment with chemotherapy as a novel strategy for effectively targeting metastasis, particularly in a neoadjuvant treatment setting.
Identifiants
pubmed: 36923551
doi: 10.1158/2767-9764.CRC-21-0117
pii: CRC-21-0117
pmc: PMC10010290
doi:
Substances chimiques
Docetaxel
15H5577CQD
Doxorubicin
80168379AG
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
456-470Subventions
Organisme : CIHR
ID : 156221
Pays : Canada
Organisme : CIHR
ID : 160398
Pays : Canada
Informations de copyright
© 2022 The Authors; Published by the American Association for Cancer Research.
Déclaration de conflit d'intérêts
No disclosures were reported.
Références
Sci Transl Med. 2017 Jul 5;9(397):
pubmed: 28679654
Breast Cancer Res. 2005;7(3):R365-73
pubmed: 15987432
BMC Cancer. 2012 Mar 07;12:82
pubmed: 22397367
Nat Rev Cancer. 2016 Apr;16(4):201-18
pubmed: 27009393
J Cell Sci. 2010 Jun 15;123(Pt 12):2135-43
pubmed: 20501702
Autophagy. 2020 Aug;16(8):1436-1452
pubmed: 31775562
Leuk Lymphoma. 2011 Feb;52(2):298-309
pubmed: 21281239
Breast Cancer Res. 2019 Jan 24;21(1):12
pubmed: 30678714
Cancer. 2013 Mar 15;119(6):1140-8
pubmed: 23065954
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Cell Oncol (Dordr). 2021 Oct;44(5):1105-1117
pubmed: 34196912
PLoS One. 2013 Apr 12;8(4):e61515
pubmed: 23593486
J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54
pubmed: 17895480
Breast Cancer Res. 2010;12 Suppl 2:S2
pubmed: 21050423
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Neoplasia. 2016 Feb;18(2):111-20
pubmed: 26936397
Breast Cancer Res. 2014 Sep 18;16(5):438
pubmed: 25231728
Nat Med. 2004 Feb;10(2):182-6
pubmed: 14704791
Int J Cancer. 2012 Jun 15;130(12):2824-34
pubmed: 21780101
Biomed Pharmacother. 2018 Oct;106:267-274
pubmed: 29966970
Nat Rev Mol Cell Biol. 2002 Aug;3(8):586-99
pubmed: 12154370
Cancer Treat Rev. 2012 Apr;38(2):101-10
pubmed: 21612875
Cancer Cell. 2011 Oct 18;20(4):538-49
pubmed: 22014578
Proc Natl Acad Sci U S A. 2017 Aug 22;114(34):E7159-E7168
pubmed: 28784776
Lancet Oncol. 2018 Jan;19(1):27-39
pubmed: 29242041
Stat Biopharm Res. 2018;10(2):112-122
pubmed: 30881603
Cell Signal. 2014 May;26(5):868-79
pubmed: 24462708
Cancer Cell. 2008 Jan;13(1):58-68
pubmed: 18167340
Sci Rep. 2015 Dec 03;5:17903
pubmed: 26632332
Dev Cell. 2015 Oct 26;35(2):162-74
pubmed: 26506306
Nat Commun. 2017 Jun 21;8:15884
pubmed: 28635961
Oncogene. 2012 Jan 19;31(3):269-81
pubmed: 21706056
Mol Biol Cell. 2015 Oct 1;26(19):3464-79
pubmed: 26246600
Sarcoma. 2020 Sep 9;2020:9010496
pubmed: 33005093
Molecules. 2016 Mar 01;21(3):290
pubmed: 26938523
Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7300-5
pubmed: 10377409
Nat Rev Cancer. 2011 Jun;11(6):393-410
pubmed: 21606941
Cancer Cell. 2003 Jun;3(6):537-49
pubmed: 12842083
Pharmacol Rev. 2006 Sep;58(3):621-81
pubmed: 16968952
J Biol Chem. 2019 Jan 18;294(3):887-901
pubmed: 30463939
J Cell Sci. 2014 Jan 15;127(Pt 2):267-75
pubmed: 24421310